Cescon Eleonora, Bolcato Giovanni, Federico Stephanie, Bissaro Maicol, Valentini Alice, Ferlin Maria Grazia, Spalluto Gianpiero, Sturlese Mattia, Moro Stefano
Department of Pharmaceutical and Pharmacological Sciences, University of Padova, via Marzolo 5, 35131 Padova, Italy.
Department of Chemical and Pharmaceutical Sciences, University of Trieste, Piazzale Europa,1 34127 Trieste, Italia.
ACS Med Chem Lett. 2020 Apr 28;11(6):1168-1174. doi: 10.1021/acsmedchemlett.0c00028. eCollection 2020 Jun 11.
Recent studies have highlighted the key role of Casein kinase 1 δ (CK1δ) in the development of several neurodegenerative pathologies, such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). So far, CK1δ inhibitors are noncovalent ATP competitive ligands and no drugs are currently available for this molecular target, hence the interest in developing new CK1δ inhibitors. The study aims to identify new inhibitors able to bind the enzyme; by a dual approach in silico/in vitro, the virtual screening has been performed on an in-house chemical library, which was previously designed and synthesized for other targets. The work can, therefore, be seen in the scaffold repurposing logic. The proposed strategy has led to the identification of two hits, having a novel scaffold in the landscape of CK1δ inhibitors and with an activity in the micromolar range.
最近的研究突出了酪蛋白激酶1δ(CK1δ)在几种神经退行性疾病发展中的关键作用,如阿尔茨海默病(AD)、帕金森病(PD)和肌萎缩侧索硬化症(ALS)。到目前为止,CK1δ抑制剂是非共价ATP竞争性配体,目前尚无针对该分子靶点的药物,因此人们对开发新的CK1δ抑制剂很感兴趣。该研究旨在鉴定能够结合该酶的新抑制剂;通过计算机辅助/体外双管齐下的方法,对一个内部化学文库进行了虚拟筛选,该文库先前是为其他靶点设计和合成的。因此,这项工作可以从支架重新利用的逻辑角度来看待。所提出的策略已导致鉴定出两个活性分子,它们在CK1δ抑制剂领域具有新型支架,且活性处于微摩尔范围内。